Skip to main content
Cellid Co., Ltd. logo

Cellid Co., Ltd. — Investor Relations & Filings

Ticker · 299660 ISIN · KR7299660001 KO Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2021-03-16 Audit Report / Informat…
Country KR South Korea
Listing KO 299660

About Cellid Co., Ltd.

http://www.cellid.co.kr

Cellid Co., Ltd. is a research and development biotechnology company focused on immunotherapeutic vaccines. The company's activities are centered on two proprietary technology platforms: CeliVax for anti-cancer immunotherapy and an adenovirus vector platform for infectious disease vaccines. The CeliVax platform is used to develop personalized vaccines that utilize a patient's own B cells and monocytes to target specific cancer antigens. The adenovirus vector platform enables the rapid development of safe, non-replicating viral vector vaccines, with a key application being its COVID-19 vaccine candidate. Cellid's pipeline is built upon these core technologies to address unmet medical needs in oncology and virology.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing titled '감사보고서 제출' (Submission of Audit Report) from the company Cellid. It provides the audit opinion (unqualified/proper), key financial data, and details regarding the external auditor (Samjong Accounting Corp). While it contains financial data, it is a summary disclosure of the audit results rather than the full Annual Report (10-K) or a standalone audit report document. According to the 'Menu vs Meal' rule, this is a formal regulatory announcement of the audit report submission, which fits the 'Audit Report / Information' (AR) category as it specifically details the audit opinion and financial summary required by regulatory standards. FY 2020
2021-03-16 Korean
사업보고서 (2020.12)
Annual Report Classification · 100% confidence The document is a comprehensive 'Business Report' (사업보고서) for the fiscal year 2020 (Jan 1, 2020 to Dec 31, 2020) for the company 'Cellid'. It contains detailed sections on company overview, history, capital changes, shareholding, and business operations. This is the standard Korean regulatory filing equivalent to a 10-K in the US market, providing full financial and operational disclosure for the fiscal year. FY 2020
2021-03-16 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Cellid Co., Ltd. It contains the meeting date, location, agenda items (financial statements, director appointments, etc.), and instructions for shareholders. This document is a formal proxy solicitation and information statement provided to shareholders to inform them of the upcoming meeting and request their votes. It fits the definition of a Proxy Solicitation & Information Statement (PSI).
2021-03-09 Korean
투자판단관련주요경영사항(국책과제 선정(아데노바이러스 벡터를 기반으로 한 코로나19 예방백신의 임상 1/2a상 개발))
Capital/Financing Update Classification · 95% confidence The document is a regulatory filing from a Korean company (Cellid) regarding a 'major management matter' (투자판단 관련 주요경영사항), specifically the selection for a government-funded project related to COVID-19 vaccine development. It does not fit into specific categories like financial reports, dividends, or director dealings. As it is a general regulatory announcement regarding business operations and project funding, it falls under the 'Regulatory Filings' category.
2021-03-02 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for the company Cellid. It outlines the date, location, and agenda items (such as financial statement approval, director appointments, and compensation limits). This type of document is a standard proxy solicitation or notice of meeting sent to shareholders to inform them of upcoming voting matters, which falls under the Proxy Solicitation & Information Statement category.
2021-02-24 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Cellid) announcing a significant change (over 30%) in its financial structure (operating profit/loss). This type of disclosure is a standard regulatory requirement in the Korean market (DART system) for reporting material financial changes before the final audit is completed. It provides key financial highlights rather than a full annual report or a press release, fitting the 'Earnings Release' (ER) category as it serves as the initial announcement of financial performance metrics. FY 2020
2021-02-24 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.